AYURF (Ayurcann Holdings) EBIT: $-2.74 Mil (TTM As of Sep. 2025)


What is Ayurcann Holdings EBIT?

Ayurcann Holdings AYURF EBIT is $-2.74 Mil as of Sep. 2025. The stock has 2 warning signs investors should review.

Ayurcann Holdings's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2025 was $-0.69 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2025 was $-2.74 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Ayurcann Holdings's annualized ROC % for the quarter that ended in Sep. 2025 was -148.42%. Ayurcann Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was -314.37%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Ayurcann Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was -955.75%.

Ayurcann Holdings  (OTCPK:AYURF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Ayurcann Holdings's annualized ROC % for the quarter that ended in Sep. 2025 is calculated as:

ROC % (Q: Sep. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Sep. 2025 ))/ count )
=-2.768 * ( 1 - 0% )/( (1.932 + 1.798)/ 2 )
=-2.768/1.865
=-148.42 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9.274 - 10.912 - ( 1.453 - max(0, 11.043 - 7.473+1.453))
=1.932

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8.232 - 10.681 - ( 0.607 - max(0, 10.811 - 6.564+0.607))
=1.798

Note: The Operating Income data used here is four times the quarterly (Sep. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Ayurcann Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Sep. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-2.768/( ( (0.92 + max(-4.894, 0)) + (0.841 + max(-4.724, 0)) )/ 2 )
=-2.768/( ( 0.92 + 0.841 )/ 2 )
=-2.768/0.8805
=-314.37 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.899 + 2.721 + 0.4) - (10.912 + 0 + 0.0019999999999989)
=-4.894

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.447 + 2.222 + 0.288) - (10.681 + 0 + 0)
=-4.724

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Ayurcann Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2025 )
=-2.743/0.287
=-955.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ayurcann Holdings EBIT Related Terms

Ayurcann Holdings EBIT Historical Data

* Premium members only.

The historical data trend for Ayurcann Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ayurcann Holdings EBIT Chart

Ayurcann Holdings Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Jun21 Jun22 Jun23 Jun24 Jun25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.30 -2.60 -3.97 -2.37 -2.07

Ayurcann Holdings Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 0.06 -0.27 -1.84 -0.69

AYURF vs BSPK, SKYI, CPMD: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ayurcann Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ayurcann Holdings EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ayurcann Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ayurcann Holdings's EV-to-EBIT falls into.


Ayurcann Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-2.74 Mil mean?
Ayurcann Holdings (AYURF) has a EBIT of $-2.74 Mil as of Sep. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ayurcann Holdings.
Is Ayurcann Holdings' EBIT too high?
Ayurcann Holdings' current EBIT is $-2.74 Mil.
How does Ayurcann Holdings' EBIT compare to BSPK and SKYI?
Ayurcann Holdings' EBIT of $-2.74 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ayurcann Holdings. Ayurcann Holdings's current EBIT is $-2.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ayurcann Holdings stock overvalued right now?
Ayurcann Holdings (AYURF) has a current EBIT of $-2.74 Mil. The stock's GF Value™ is $0.01, compared to a current price of $0.00 — trading 79% below its estimated fair value. The current EBIT is $-2.74 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Ayurcann Holdings (AYURF), the current EBIT is $-2.74 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ayurcann Holdings Business Description

Address 1080 Brock Road, Unit 6, Pickering, ON, CAN, L1W 3H3
Ayurcann Holdings Corp is engaged in providing post-harvest outsourcing solutions to licensed cannabis producers and the manufacture and distribution of cannabis products.